Skora Andrew D, Douglass Jacqueline, Hwang Michael S, Tam Ada J, Blosser Richard L, Gabelli Sandra B, Cao Jianhong, Diaz Luis A, Papadopoulos Nickolas, Kinzler Kenneth W, Vogelstein Bert, Zhou Shibin
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; Howard Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287;
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9967-72. doi: 10.1073/pnas.1511996112. Epub 2015 Jul 27.
Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We here describe an approach to identify single-chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by HLA molecules. We demonstrate that these scFvs can be successfully converted to full-length antibodies, termed MANAbodies, targeting "Mutation-Associated Neo-Antigens" bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for mutant peptides bound to predefined HLA types. In this way, we obtained two scFvs, one specific for a peptide encoded by a common KRAS mutant and the other by a common epidermal growth factor receptor (EGFR) mutant. The scFvs bound to these peptides only when the peptides were complexed with HLA-A2 (KRAS peptide) or HLA-A3 (EGFR peptide). We converted one scFv to a full-length antibody (MANAbody) and demonstrate that the MANAbody specifically reacts with mutant peptide-HLA complex even when the peptide differs by only one amino acid from the normal, WT form.
癌症基因编码的突变表位几乎总是位于细胞内部,使得它们无法被传统抗体识别。我们在此描述一种方法,用于鉴定由HLA分子呈递在细胞表面的突变肽特异性单链可变片段(scFv)。我们证明,这些scFv能够成功转化为全长抗体,即靶向与HLA结合的“突变相关新抗原”的MANA抗体。首先设计并构建了一个代表高度多样化单链可变片段序列阵列的噬菌体展示文库。然后使用竞争性筛选方案来鉴定与预定义HLA类型结合的突变肽特异性克隆。通过这种方式,我们获得了两个scFv,一个对常见KRAS突变体编码的肽具有特异性,另一个对常见表皮生长因子受体(EGFR)突变体编码的肽具有特异性。这些scFv仅在肽与HLA-A2(KRAS肽)或HLA-A3(EGFR肽)复合时才与这些肽结合。我们将一个scFv转化为全长抗体(MANA抗体),并证明该MANA抗体即使在肽与正常野生型形式仅相差一个氨基酸时,也能与突变肽-HLA复合物特异性反应。